AU2020903781A0 - Pharmaceutical formulations - Google Patents
Pharmaceutical formulationsInfo
- Publication number
- AU2020903781A0 AU2020903781A0 AU2020903781A AU2020903781A AU2020903781A0 AU 2020903781 A0 AU2020903781 A0 AU 2020903781A0 AU 2020903781 A AU2020903781 A AU 2020903781A AU 2020903781 A AU2020903781 A AU 2020903781A AU 2020903781 A0 AU2020903781 A0 AU 2020903781A0
- Authority
- AU
- Australia
- Prior art keywords
- pharmaceutical formulations
- formulations
- pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/AU2021/051212 WO2022082257A1 (en) | 2020-10-19 | 2021-10-18 | Oral cannabinoid formulation comprising medium chain triglycerides and tocopheryl phosphates |
US18/249,647 US20230381208A1 (en) | 2020-10-19 | 2021-10-18 | Oral cannabinoid formulation comprising medium chain triglycerides and tocopheryl phosphates |
AU2021366254A AU2021366254A1 (en) | 2020-10-19 | 2021-10-18 | Oral cannabinoid formulation comprising medium chain triglycerides and tocopheryl phosphates |
CA3195938A CA3195938A1 (en) | 2020-10-19 | 2021-10-18 | Oral cannabinoid formulation comprising medium chain triglycerides and tocopheryl phosphates |
IL302169A IL302169A (en) | 2020-10-19 | 2021-10-18 | Oral cannabinoid formulation comprising medium chain triglycerides and tocopheryl phosphates |
EP21881370.7A EP4228613A1 (en) | 2020-10-19 | 2021-10-18 | Oral cannabinoid formulation comprising medium chain triglycerides and tocopheryl phosphates |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2020903781A0 true AU2020903781A0 (en) | 2020-11-12 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4045480A4 (en) | Pharmaceutical formulations | |
EP3946316A4 (en) | Cannabidiol pharmaceutical compositions | |
EP4028059A4 (en) | Stable medicinal cannabidiol compositions | |
EP4015001A4 (en) | Oral pharmaceutical composition | |
EP4048276A4 (en) | Solid pharmaceutical formulations comprising ticagrelor | |
GB202010230D0 (en) | Pharmaceutical formulation | |
EP3946296A4 (en) | Extended release pharmaceutical formulation | |
EP4058025A4 (en) | Pharmaceutical compositions comprising ticagrelor | |
IL297081A (en) | Pharmaceutical formulation | |
EP3914234A4 (en) | Pharmaceutical compositions | |
EP4034115A4 (en) | Pharmaceutical composition comprising thrombolytic peptide-tetrahydroisoquinoline conjugate | |
EP3746080A4 (en) | Pharmaceutical formulations | |
EP3984549A4 (en) | Medicinal composition | |
AU2020903781A0 (en) | Pharmaceutical formulations | |
AU2020903780A0 (en) | Pharmaceutical formulations | |
EP3949952A4 (en) | Medicinal composition | |
TWI800878B (en) | Drug set | |
ZA202212663B (en) | Pharmaceutical formulations | |
IL308250A (en) | Pharmaceutical formulations | |
GB202112820D0 (en) | Pharmaceutical formulations | |
AU2020903873A0 (en) | Lymph-Targeting Formulations | |
AU2020901866A0 (en) | Immugenic formulations | |
GB202005282D0 (en) | Pharmaceutical Formulations | |
GB202003108D0 (en) | Pharmaceutical formulations | |
EP4129276A4 (en) | Pharmaceutical composition |